RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases.
RXi was founded by world-leading researchers in the field of RNAi, began operations in January of 2007 and started trading on the Nasdaq in March of 2008